secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001867096-24-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility
--------------------------------------------------------------------------------

- Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.
- Net loss in Q4 $13.4M ($0.10 loss per share); year-end cash $72.5M.
- FY2024 guidance: total net revenue $170M-$200M; year-end cash $55M-$75M.
- Refinanced existing $150M Hayfin loan with new $200M term loan; additional $15.2M available to redeem 2025 notes.
- New loan bears 6.95% + SOFR (floor 2%) interest; maturity March 2029; reduces borrowing cost by 2.05%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/0001867096-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000024/xers-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer